Lung cancer

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a…

6 months ago

Translational Science Update of Precision Oncology Methods in Lung Cancer

Presented by: Joel W Neal, MD. PhD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth…

1 year ago

Clinical Application of Precision Oncology in Lung Cancer

Presented by: Millie Das, MD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center,…

1 year ago

Basic Science & Molecular Pathogenesis of Lung Cancer

Presented by: Alex A. Adjei, MD, PhD, FACP Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit,…

1 year ago

Overview of KEYNOTE-671 & NADIM II

By Dr. Lei Deng University of Washington & Fred Hutch         Watch Dr. Lei Deng's overview of…

1 year ago

FDA grants approval to Pralsetinib for NSCLC With RET Fusion Mutation

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 9, 2023, the U.S. Food and Drug Administration granted regular approval…

1 year ago

Updates from ASCO: KEYNOTE-789 and NSCLC

By Dr. Aakash Desai Mayo Clinic   KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant,…

1 year ago

ASCO23 – LUNAR Study Summary

Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center   Live report from ASCO23, Chicago, IL June 6, 2023  …

1 year ago

ASCO23 – WU-KONG6 Trial Summary

Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center   Live report from ASCO23, Chicago, IL June 6, 2023  …

1 year ago

AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer

By Dr. Dipesh Uprety Karmanos Cancer Institute   Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the…

2 years ago